Clinical Trial Update: A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Vebreltinib in combination with platinum-containing regimens in MET-positive non-small cell lung cancer, currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Vebreltinib (vebreltinib)

Snippet

Sponsor: Beijing Pearl Biotechnology Limited Liability Company | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: RECRUITING